top of page

Milan based Enthera Pharmaceuticals is working in the autoimmune space with an asset that targets a unique pathway and that is the result of local research

  • Oct 17, 2024
  • 1 min read

CEO Lisa Olson describes the IGFBP3/TMEM219 axis and the antibody Enthera has designed to target it, all of which are the result of research done at Milan’s San Raffaele Scientific Institute by the company’s founder and CSO Paolo Fiorina.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page